The primary objective of the study is to determine the effect of seralutinib on improving exercise capacity in subjects with WHO Group 1 PAH who are FC II or III. The secondary objective for this trial is to determine time to clinical worsening.
- Investigator
- Ali Ataya
- Ages
- 18 Years - 75 Years
- Sexes
- All